Compare Medpace Holdings Inc (MEDP) vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF (PDBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF trades at $19.66 (market cap $7.77B). The key difference: Medpace Holdings Inc is far larger — about 2.2× Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 6,100,303). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF for 56 Days on average.
| MEDP | PDBC | |
|---|---|---|
Market Cap | $16.82B | $7.77B |
Volume | 223,093 | 6,100,303 |
Sector | Health | — |
52-Week High | $630.19 | $20.10 |
52-Week Low | $393.42 | $13.16 |
Typical Hold Time | 14 Days | 56 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
PDBC (Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF) trades at $19.66, up 1.29% with strong bullish technical signals from moving averages. The ETF has delivered impressive performance with 45.66% year-to-date gains through Q3 2026, driven by energy and agricultural commodity strength amid geopolitical tensions. Recent institutional activity shows mixed sentiment with significant short interest growth of 215.4% in September offset by multiple institutional purchases.
The commodity ETF outlook remains positive given ongoing geopolitical risks and defensive sector rotation, though elevated short interest and overbought RSI readings suggest near-term consolidation risk. Commodity super-squeeze warnings from HSBC highlight potential upside while defensive ETF inflows support continued institutional demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Invesco Optimum Yld Dvsfd Cmd Str No K 1 ETF
The fund is an actively managed exchange-traded fund ("ETF") that seeks to achieve its investment objective by investing in a combination of financial instruments that are economically linked to the world's most heavily traded commodities. Commodities are assets that have tangible properties, such as oil, agricultural produce or raw metals.
Read more on PDBC →
